Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CCK/gastrin antagonists--clinical perspectives

J Calam

    Acta Gastro-Enterologica Belgica
    |May 1, 1993
    PubMed
    Summary
    This summary is machine-generated.

    Two cholecystokinin (CCK)/gastrin receptor types exist. CCKA antagonists impact gut function and may treat gastrointestinal disorders, while CCKB antagonists show potential for acid-peptic disease and cancer therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lectins: from basic science to clinical application in cancer prevention.

    Expert opinion on investigational drugs·2005
    Same author

    Effects of Ostertagia ostertagi and omeprazole treatment on feed intake and gastrin-related responses in the calf.

    Veterinary parasitology·2002
    Same author

    ABC of the upper gastrointestinal tract: Pathophysiology of duodenal and gastric ulcer and gastric cancer.

    BMJ (Clinical research ed.)·2001
    Same author

    Comparison of the effects of concanavalin-A and epidermal growth factor on epithelial cell proliferation in the rat intestine.

    Alimentary pharmacology & therapeutics·2001
    Same author

    Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonist.

    Gut·2001
    Same author

    Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C.

    Gut·2001

    Area of Science:

    • Gastroenterology and Pharmacology
    • Neuroscience

    Background:

    • Two distinct receptor types for cholecystokinin (CCK)/gastrin peptides have been identified.
    • Specific antagonists are available for both CCKA and CCKB receptors, enabling targeted research and therapeutic exploration.

    Purpose of the Study:

    • To explore the physiological roles and potential therapeutic applications of CCKA and CCKB receptor antagonists.
    • To evaluate the effects of CCKA antagonists on gastrointestinal functions and potential clinical uses.
    • To investigate the impact of CCKB antagonists on acid secretion, tumor growth, and central nervous system effects.

    Main Methods:

    • Administration of specific CCKA and CCKB receptor antagonists in preclinical and clinical models.
    • Assessment of pancreatic enzyme secretion, gastrointestinal transit times, and gallbladder contraction.

    Related Experiment Videos

  • Evaluation of gastrin-stimulated acid secretion and tumor cell growth.
  • Analysis of anxiolytic-like effects in animal models.

    • Main Results:

    • CCKA antagonists inhibit pancreatic enzyme secretion and shorten gastrointestinal transit times, with potential applications in anorexia and constipation.
    • CCKA antagonists markedly inhibit gallbladder contraction, leading to gallstone formation in baboons, a critical consideration for human use.
    • CCKB antagonists inhibit gastrin-stimulated acid secretion and show promise in treating gastrin-dependent tumors, including colon cancer.
    • CCKB antagonists exhibit potent anxiolytic-like effects in animals, suggesting a primary clinical application in anxiety disorders.

    Conclusions:

    • CCKA receptor antagonists offer therapeutic potential for various gastrointestinal disorders but require careful management to avoid adverse effects like gallstone formation.
    • CCKB receptor antagonists present promising avenues for treating acid-peptic diseases and certain cancers, with a significant potential application in managing anxiety.
    • Targeting CCK/gastrin receptors provides a versatile strategy for addressing a range of medical conditions affecting the gut, brain, and cellular proliferation.